Unicycive Therapeutics Receives FDA Guidance On Renazorb Regulatory Pathway

Unicycive Therapeutics Inc UNCY updated the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). 

  • Renazorb is a second-generation lanthanum-based phosphate-binding agent utilizing proprietary nanoparticle technology for hyperphosphatemia in patients with chronic kidney disease (CKD).
  • In a recent Type C interaction with the FDA, Unicycive sought the FDA's feedback on the sufficiency of the Renazorb data package to support a 505(b)(2) new drug application (NDA) submission. 
  • Unicycive provided results from in vitro studies conducted to support the comparability of Renazorb and its active lanthanum moiety to the approved product Fosrenol. 
  • The FDA confirmed in their response that the phosphate-binding mechanism and stoichiometry of Renazorb are comparable to Fosrenol.
  • Together with the previously agreed-upon 6-month mouse toxicology, the additional bioequivalence study will provide the necessary bridge to support the NDA submission. 
  • No additional pre-clinical or clinical studies are currently expected to be required in support of an NDA submission for Renazorb.
  • See here Benzinga's Full FDA Calendar.
  • The Company reaffirmed its previous guidance to submit an NDA for Renazorb in Q4 of 2022.
  • Price Action: UNCY shares are down 2.40% at $2.85 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!